explore -WSS

explore

author：comprehensive 2025-09-27 09:46:50 - browse：7

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Microbiome research is starting to find links to chronic diseases

focus

WSS

Living organ donors deserve priority status for transplants

Biotech stock slump in 2023: awaiting the turnaround

Biden administration plans revamp of organ transplant system

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

CommonSpirit Health keeps growing, even as it loses money

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

entertainment

explore

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Reanimated hearts work just as well for transplants, study finds

DIEP, the 'gold standard' of breast reconstruction, is under threat

Thermo Fisher plant for manufacturing gene therapies to expand

Guidelines to prevent youth baseball injuries need more muscle

FDA panel to weigh approval of NurOwn, controversial ALS drug

Wildfire smoke exposes gaps in outdoor worker protections

Changes to biosimilar regulatory framework must prioritize patients

Guidelines to prevent youth baseball injuries need more muscle

Drug for rare kidney disease narrowly misses mark in clinical trial

entertainment

Bispecific antibodies are next new thing in cancer immunotherapy

Biotech stock slump in 2023: awaiting the turnaround

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

EpiPen alternative approval delay highlights citizen petition issue

Biogen nominates mother of director’s child to replace him on board

FDA approves first new drug developed for postpartum depression

focus

hotspot

leisure time

knowledge